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Abstract
Diisocyanates are the most common cause of occupational asthma, but risk factors are not well 
defined. A case-control study was conducted to investigate whether genetic variants in 
inflammatory response genes (TNFα, IL1α, IL1β, IL1RN, IL10, TGFB1, ADAM33, ALOX-5, 
PTGS1, PTGS2 and NAG-1/GDF15) are associated with increased susceptibility to diisocyanate 
asthma (DA). These genes were selected based on their role in asthmatic inflammatory processes 
and previously reported associations with asthma phenotypes. The main study population 
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consisted of 237 Caucasian French Canadians from among a larger sample of 280 diisocyanate-
exposed workers in two groups: workers with specific inhalation challenge (SIC) confirmed DA 
(DA+, n = 95) and asymptomatic exposed workers (AW, n = 142). Genotyping was performed on 
genomic DNA, using a 5′ nuclease PCR assay. After adjusting for potentially confounding 
variables of age, smoking status and duration of exposure, the PTGS1 rs5788 and TGFB1 
rs1800469 single nucleotide polymorphisms (SNP) showed a protective effect under a dominant 
model (OR = 0.38; 95% CI = 0.17, 0.89 and OR = 0.38; 95% CI = 0.18, 0.74 respectively) while 
the TNFα rs1800629 SNP was associated with an increased risk of DA (OR = 2.08; 95% CI = 
1.03, 4.17). Additionally, the PTGS2 rs20417 variant showed an association with increased risk of 
DA in a recessive genetic model (OR = 6.40; 95% CI = 1.06, 38.75).These results suggest that 
genetic variations in TNFα, TGFB1, PTGS1 and PTGS2 genes contribute to DA susceptibility.
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(SNP)
Introduction
Diisocyanates, low-molecular weight reactive chemicals used in diverse industrial processes, 
are one of the most frequently reported causes of occupational asthma in the work-place. 
Toluene diisocyanate (TDI), 4,4′-diphenylmethane diisocyanate (MDI) and hexamethylene 
diisocyanate (HDI) are the most commonly used monomers in industry and estimated to 
cause asthma in 5–15% of workers with long-term exposure (Bernstein, 1996; Wisnewski & 
Redlich, 2001). Diisocyanates bind selectively to human proteins and these protein 
conjugates act as antigens that induce airway inflammation with the release of inflammatory 
mediators. Of these mediators, cytokines play a critical role in asthma pathogenesis by 
orchestrating the allergic inflammatory response (Maestrelli et al., 1995). Elevated levels of 
both T-helper (TH)-1 and TH2 cytokines have been demonstrated in the airways of subjects 
with different asthma phenotypes, supporting the heterogenic nature of disease (Broide et 
al., 1992; Fisseler-Eckhoff et al., 2011; Maestrelli et al., 1995, 1997; Mapp et al., 2009; 
Piirila et al., 2008). Animal and in vitro models revealed multiple roles of cytokines in non-
specific inflammatory processes as well as specific immune events in response to 
diisocyanate exposure (Chiung et al., 2010; Matheson et al., 2002; Swierczynska-Machura et 
al., 2012).
Although many studies investigated the association between single nucleotide 
polymorphisms (SNP) in pro-inflammatory cytokine genes and asthma phenotypes (Che et 
al., 2014; Padron-Morales et al., 2013; Panek et al., 2014; Savenije et al., 2011; Zeyrek et al., 
2008), there is only one study that focused on DA. Beghé et al. (2004) studied tumor 
necrosis factor-α (TNFα) A-308G polymorphism in TDI-induced asthma but found no 
significant difference in frequency of this variant between cases and asymptomatic exposed 
subjects. The interleukin-1 (IL1), IL10, TNFα and transforming growth factor-β (TGFB1) 
genes have not previously been studied in relation to DA susceptibility.
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Other genes focused on in this study included ADAM33 (ADAM metallopeptidase domain 
33), PTGS1 (prostaglandin-endoperoxide synthase-1, previously COX1), PTGS2 (previously 
COX2), ALOX5 (arachidonate 5-lipoxygenase) and NAG-1/GDF15 (non-steroidal anti-
inflammatory drug-activated gene). ADAM33 is the first reported asthma-susceptibility gene 
identified by positional cloning (van Eerdewegh et al., 2002). It is highly expressed in 
epithelium and airway smooth muscle cells and plays an important role in airway 
remodeling (Tripathi et al., 2014). It has been suggested that altered ADAM33 protein 
function may promote inflammation through impaired or enhanced release of cytokines and 
growth factors (Cakebread et al., 2004). Cyclo-oxygenases are key enzymes that catalyze the 
biosynthesis of prostaglandins, which are essential mediators of inflammation in asthma 
(Dubois et al., 1998). ALOX5 is the first enzyme in the biosynthetic pathway leading to the 
production of leukotrienes and plays an important role in allergic and inflammatory diseases 
(Duroudier et al., 2009; Radmark et al., 2007). NAG-1/GDF15 is a member of the TGFβ 
cytokine superfamily that plays an important role in controlling inflammatory responses by 
reducing leukocyte recruitment and maintaining homeostasis (Zarbock & Rossaint, 2011). 
Numerous studies showed associations between genetic variants of PTGS1, PTGS2, 
ADAM33 and ALOX5 genes and allergic asthma, but these variations have not been studied 
for association with DA (Holloway et al., 2008; Shi et al., 2005, 2008; Song et al., 2013). In 
addition, the NAG1/GDF15 variants were not explored in asthma phenotypes.
Since the impact of a given gene on the phenotype is influenced by occupational and 
environmental exposures, gene–environment interaction explains phenotype variance better 
than two factors considered separately. Occupational asthma (OA) is an excellent model for 
studying gene–environment interactions since the causal agent can be identified with 
specific inhalation challenge (SIC) and the lag period between initial exposure and onset of 
sensitization and clinical symptoms can be followed. Therefore, it is important to study 
asthma candidate genes in OA since different occupational and environmental exposures 
might have a different effect on the phenotype. Based on their role in asthma pathogenesis 
and previously reported associations with asthma phenotypes, the present candidate gene 
association study was designed to investigate the role of SNP in a group of inflammatory 
response genes as predictors of susceptibility to DA. The identification of variations in 
specific genes involved in the DA process might lead to a better understanding of the 
underlying disease pathways and, thus, guide for the development of more effective 
therapeutic and preventive strategies.
Materials and methods
Study participants
The main study population consisted of 237 Caucasian French Canadians from among a 
larger sample of 280 diisocyanate (HDI, MDI and TDI)-exposed workers. The main study 
analyses were conducted on only the Caucasian French Canadians to avoid the possibility of 
bias due to population stratification (Heiman et al., 2004). Also, the numbers of subjects 
recruited from other non-Caucasian-French Canadian and Spanish populations were too 
small to independently support statistical modeling. However, identical statistical analyses 
were also conducted on the entire sample and the results are presented as supplementary 
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data. Of the 237 participants, 95 workers were diagnosed with DA (DA+) based on a positive 
specific inhalation challenge (SIC) test, while 142 HDI-exposed asymptomatic workers 
(AW) served as controls. We did not perform a separate analysis on HDI-induced DA+ cases 
and controls since the majority of DA+ subjects were exposed to HDI and overall numbers 
would be too small for meaningful statistical analysis.
Symptomatic subjects were recruited from occupational pulmonary disease clinics located in 
Canada (Sacre Coeur Hospital, Montreal; Laval Hospital, Sainte-Foy; University Health 
Network, Toronto) and Spain (Fundacion Jimenez Diaz, Madrid and Hospital Vall d’Hebron, 
Barcelona). The subjects underwent SIC with the appropriate work-relevant diisocyanate 
chemicals according to previously described protocols (Malo et al., 1999; Sastre et al., 
2003). A decrease in FEV1 of at least 20% from pre-challenge baseline during the early 
and/or late asthmatic response was defined as a positive SIC test. AW controls were 
recruited in Quebec (Canada) from HDI-exposed painters. Data regarding age, sex, ethnicity, 
smoking status, time of exposure and respiratory symptoms were collected by questionnaire. 
Atopy was evaluated by skin prick testing to common aeroallergens, defined by a positive 
reaction of at least 3 mm greater than saline control for at least one allergen. Whole blood 
was collected for genetic testing. All subjects gave informed consent and the study protocol 
is approved and renewed annually by Institutional Review Boards of the National Institute 
for Occupational Safety and Health and each participating institution.
Genotyping
Genomic DNA was extracted from whole blood samples using the QIAamp blood kit 
(QIAGEN Inc., Chatsworth, CA). Genotyping was performed on genomic DNA, using a 5′ 
nuclease PCR assay. Primers and probes were designed, using the Assay-by-Design™ 
service from Applied Biosystems (Foster City, CA). PCR amplification was performed in a 
volume of 25 μl containing 10 ng genomic DNA, 12.5 μl 2X Taqman® Universal Master 
Mix, 200 nM probe and 900 nM primer. Cycling conditions were 50°C for 2 min and 95°C 
for 10 min, followed by 50 cycles at 92°C for 30 s and 60°C for 1 min. Amplification was 
performed using a StepOnePlus™ Real-Time PCR System (Applied Biosystems). Positive 
and negative controls were used within each run of PCR amplification. All samples with 
ambiguous results were repeated, as were a random selection of 10% of all samples to 
ensure laboratory quality control.
Statistical analyses
Comparisons between groups on demographic variables were analyzed using chi-square 
tests or analysis of variance for discrete and continuous variables, respectively. Initial 
analyses, including tests for Hardy–Weinberg Equilibrium (HWE), allele and genotype 
frequencies were calculated using the Fisher’s Exact Test. Unadjusted odds ratios (OR) were 
calculated using contingency tables. Adjusted ORs were calculated using logistic regression 
while adjusting for age, exposure time (months) and smoking status (current/ex/never). Sex 
and atopy were not significant in any models and were not included in the final analysis. 
Since underlying genetic models are unknown a priori, the association between each SNP 
and DA status was analyzed using three genetic models. These include a dominant model 
(comparing homozygous wild-type genotype with variant allele-carrying genotypes), a 
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recessive model (comparing wild-type allele-carrying genotypes with homozygous variant 
genotype) and an additive model. All statistical analyses were performed using SAS 9.2 
(SAS Institute, Cary, NC). SNAP2 tools were used to update annotations of significant SNP 
according to dbSNP135 and to find proxy SNP within 500 kb based on linkage 
disequilibrium (LD) and physical distance (Johnson et al., 2008). Since SNP located in a 
genomic region with various transcription factor (TF) binding sites are more likely to 
influence transcriptional regulation, we searched functional elements overlapping with the 
selected SNP. RegulomeDB was used to annotate SNP with known and predicted regulatory 
elements (Boyle et al., 2012).
Results
Subject characteristics
The demographic characteristics of the study groups included in the statistical analyses are 
described in Table 1. The participants included in this analysis were Caucasian French-
Canadians. Mean age was higher in the DA+ group than AW controls (42.4 versus 30.4 
years). While the DA+ group consisted of subjects exposed to HDI, MDI and TDI 
(53:22:20), AW controls were exposed only to HDI in the workplace. AW controls had less 
duration of exposure to diisocyanates than the DA+ group (65.8 versus 144.6 months). The 
prevalence of smoking was significantly different between the DA+ group and AW controls 
(p < 0.0001). The frequency of atopy was similar between the two groups (58.9% in DA+, 
53.5% in AW controls). Allele frequencies in the control population were similar to those 
determined in other studies involving Caucasian populations and were in HWE (data not 
shown). Demographic characteristics of the initial study sample are shown in Supplementary 
Table 1.
Genotype distribution and genetic models
Table 2 shows the distribution of genotypes in the study population and the p values 
represent the comparison of the proportions of genotypes between two groups. The 
frequency of the PTGS2 rs20417 SNP showed only a marginal significance between the 
DA+ group and AW controls (p = 0.057) in the univariate analysis.
Table 3 presents the results of the logistic regression model after adjusting for potentially 
confounding variables of age, smoking status and duration of exposure. In a dominant 
model, the PTGS1 rs5788 and TGFB1 rs1800469 SNP were associated with a protection 
against DA (OR = 0.38; 95% confidence interval (CI) = 0.17, 0.89, p = 0.026 and OR = 
0.38; 95% CI = 0.18, 0.74, p = 0.005) while the TNFα rs1800629 SNP conferred an 
increased risk of disease (OR = 2.08; 95% CI = 1.03, 4.17, p = 0.041). On the other hand, 
the PTGS2 rs20417 SNP showed an association with an increased risk of DA in a recessive 
model (OR = 6.40; 95% CI = 1.06, 38.75, p = 0.043). This SNP also showed a trend towards 
significance in an additive model (OR = 5.99; 95% CI = 0.98, 36.57, p = 0.053). Results of 
analyses on the larger sample that included subjects from Spain and non-Caucasian French 
Canadians were similar to those in Tables 2 and 3, suggesting population stratification did 
not bias the findings (Supplementary Tables 2 and 3).
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Regulatory information for significant associations
The four significant SNP identified from data analysis were used as inputs to the SNAP SNP 
Annotation and Proxy Search tools to update SNP IDs according to dbSNP135 and to find 
additional SNP in complete LD (r2 = 1). This led to the identification of an additional 17 
correlated SNP using data from the International HapMap Project (International HapMap 
Consortium et al., 2010). The total set of 21 SNP was then used as input to the RegulomeDB 
web resource, which integrates data from the ENCODE projects and other data sources 
regarding various types of functional assays including DNaseI-seq, ChIP-seq, RNAseq and 
eQTL analyses (Boyle et al., 2012). RegulomeDB scores of all the significant and correlated 
SNPs are presented in Supplementary Table 4. Two SNPs (TGFB1 rs1800469 and TNFα 
rs1800629) were likely to affect binding and linked to expression of a gene target 
(MGC4093 and AIF, respectively) (RegulomeDB scores = 1b and 1f, respectively). The 
PTGS2 rs20417 SNP was also likely to affect binding with a RegulomeDB score of 2b. 
There were no regulatory data available for the PTGS1 rs5788 SNP. Table 4 shows the SNP 
with RegulomeDB scores between 1–3 (scoring refers to available data types supporting a 
functional role for the variant). All SNP with putative regulatory function (RegulomeDB 
Score 1–6) are given in Supplementary Table 5.
Discussion
This is the first comprehensive study to explore potential associations of genetic variants in 
inflammatory genes with DA. The allele frequencies of 19 SNP in 11 genes were determined 
in a Caucasian worker population of European background. Two SNP in TNFα and TGFB1 
genes were significantly associated with DA. TNFα is one of the major pro-inflammatory 
cytokines located within the human major histocompatibility complex (MHC). This region 
has been repeatedly linked to asthma (Daniels et al., 1996; Xu et al., 2001). Previous studies 
demonstrated increased levels of TNFα in asthmatic airways and reported an association of 
TNFα rs1800629 (A-308G) SNP with asthma phenotypes as well as elevated total serum 
IgE levels (Ricciardolo et al., 2013; Sharma et al., 2006; Shin et al., 2004; Witte et al., 
2002). A recent meta-analysis involving 34 studies confirmed these findings and reported 
rs1800629 SNP as a risk factor for asthma (Yang et al., 2014). The -308A allele has been 
associated with increased expression levels of TNFα in stimulated human white blood cells 
(Wilson et al., 1997). In our analysis, carriage of the -308A allele was associated with an 
increased risk of DA.
Beghè et al. (2004) investigated this SNP in TDI-induced asthma, but did not find any 
association. The difference between two study results could be related to differences in 
population genetic structure and type of diisocyanate exposure. We found that the rs1800629 
SNP (RegulomeDB score, 1f) is an eQTL (expression quantitative trait loci) for AIF1 gene 
(Allograft Inflammatory Factor 1) and is situated in the Sp1 (specificity protein 1) binding 
motif. AIF1 is also located in the MHC region and is induced by cytokines. It is suspected 
that AIF1 is involved in the regulation of vascular smooth muscle cell growth. Sp1 is a 
ubiquitously expressed transcriptional activator protein that binds GC-rich regions of DNA 
to regulate gene transcription (Suske, 1999; Tan & Khachigian, 2009). Sp1 has been shown 
to be involved in the regulation of VEGF transcription that is a critical mediator of asthma 
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pathogenesis. Clifford et al. (2012) suggested that increased Sp1 binding might contribute to 
elevated VEGF secretion in asthmatics. Sp1 was also found to be one of the transcription 
factors involved in the regulation of basal and inducible 5-lipoxygenase gene transcriptions 
(Silverman et al., 1998). It is possible that the TNFα rs1800629 SNP alters Sp1 binding to 
this region and influences downstream biological processes.
The other significantly associated SNP (rs1800469, -509 C/T) is located in the promoter 
region of the TGFB1 gene. TGFB1 is an immunoregulatory cytokine that is increased in the 
airways of asthmatic individuals (Ohno et al., 1996). The rs1800469 is located within a YY1 
(Ying Yang 1) consensus binding site and is known to regulate transcriptional activity 
(Silverman et al., 2004). The rs1800469 SNP has been associated with elevated gene 
expression and circulating TGFB1 and IgE levels (Grainger et al., 1999; Jacob et al., 2013). 
Increased transcriptional activity of the T allele, as compared to the C allele, has been 
reported (Grainger et al., 1999). While some studies showed an association between variant 
rs1800469 and allergic asthma (Li et al., 2007; Pulleyn et al., 2001; Sharma et al., 2009; 
Silverman et al., 2004; Wu et al., 2010; Yang et al., 2011), others reported no association 
with asthma or other allergies (Buckova et al., 2001; Hobbs et al., 1998). In our analysis, 
carriage of the T allele was associated with a protection against DA. TGFB1 is a potent 
suppressor of inflammation and found to be protective in acute animal models of asthma 
(Alcorn et al., 2007; Li et al., 2006; Nakao et al., 2000). On the other hand, excess TGFB1 
activity was reported to induce fibrosis, pulmonary inflammation and structural remodeling 
(Crosby & Waters, 2010; McMillan et al., 2005). This is the first report showing an 
association between TGFB1 rs1800469 variant and DA. Our findings are consistent with the 
immunomodulatory role of TGFB1 in the asthmatic process and suggest that the same SNP 
could be protective or adverse depending on environmental and other genetic factors.
In line with previous observations, RegulomeDB showed evidence of regulatory function for 
the rs1800469 SNP (score, 1b). RegulomeDB cites rs1800469 is an eQTL for MGC4093, 
affects binding of POLR2A, CREBBP, CTCF and falls within the COUPTF binding motif. 
MGC4093 is one of the two genes (the other is MGC2055) with unknown function in the 30 
kb region surrounding the TGFB1 gene. This gene lies between TGFB1 rs1800469 and 
rs7045 and its transcripts have been reported in various UniGene libraries of lung tissue. The 
genomic region including TGFB1 and MGC4093 is organized in two large haplotype blocks 
in Caucasians. Based on association and LD patterns and the fact that only TGFB1 spans 
both of these haplotype blocks, the MGC4093 has been ruled out as a modifier of other 
lungs diseases such as chronic obstructive pulmonary disease and cystic fibrosis. TGFB1 
SNPs were proposed as a likely modifier of these diseases (Celedon et al., 2004; Drumm et 
al., 2005). Although these findings need to be replicated in an independent sample, our 
results are consistent with previous observations and suggest TGFB1 rs1800469 SNP as a 
likely modifier of DA.
One of the proteins affected by this SNP is CTCF (the transcription regulator CCCTC-
binding factor). It is a DNA insulator protein with the ability to block enhancers from 
activating their target genes via chromatin remodeling. CTCF was found to be essential for 
the GATA3/SATB1-mediated regulation of the TH2 cytokine gene expression (Ribeiro de 
Almeida et al., 2009). Other affected protein CREBBP (CREB binding protein) is one of the 
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transcriptional co-activators with intrinsic histone acetyltransferase (HAT) activity. HAT and 
histone deacetylase (HDAC) regulate chromatin acetylation and likely play a key role in 
induction of inflammatory genes. Several studies reported an imbalance between activities 
of HATs and HDAC in bronchial biopsies, alveolar macrophages and peripheral blood 
mononuclear cells in asthma (Cosio et al., 2004; Ito et al., 2002). POLR2A (RNA II 
Polypeptide A) is a DNA-dependent RNA polymerase catalyzing transcription of DNA into 
RNA. The rs1800469 variant may play an important role in affecting the binding of these 
regulatory proteins and consequently the risk of DA. The same SNP is also situated in the 
COUP binding motif. COUPTFs (COUP transcription factor) are transcription factors that 
play key roles in the development and function of the immune system (Leid et al., 2004). It 
is possible that the overlap between rs1800469 and this binding motif influence the optimal 
expression of particular inflammatory genes. Examining these interactions in the context of 
DA pathogenesis could yield additional insight into the molecular mechanisms involved.
The PTGS2 rs20417 is located within the promoter region and the -765C allele has been 
shown to have significantly lower promoter activity in vitro compared with the -765G allele 
(Papafili et al., 2002). PTGS2 is highly inducible by mitogenic and pro-inflammatory stimuli 
and involved in the regulation of inflammatory responses. Increased expression of PTGS2 is 
observed in the airway epithelium and submucosa of asthmatics (Sousa et al., 1997; Taha et 
al., 2000). While some studies reported associations of PTGS2 SNPs with asthma 
phenotypes (Chan et al., 2007; Shi et al., 2008; Szczeklik et al., 2004), others found no 
relationship (Shi et al., 2004). In our analysis, the PTGS2 rs20417 SNP conferred an 
increased risk of DA with an OR of 6.4 and showed evidence of regulatory function 
(RegulomeDB score, 2b). The rs20417 SNP has indications for binding TFAP2A 
(transcription factor AP-2 alpha), TFAP2C (Transcription Factor AP-2 Gamma) proteins. 
However, results of this interaction in the asthmatic process are unknown. This SNP is also 
located in the binding motifs for STAT1, E2F and EWSR1-FLI1. STAT (Signal transducer 
and activator of transcription) transcription factors play critical roles in regulating cell 
growth and differentiation, homeostasis and the immune response (Horvath, 2000; Ramana 
et al., 2000). E2F transcription factors are involved in the regulation of cell cycle and DNA 
replication in mammalian cells (Cam & Dynlacht, 2003). EWSR1 (EWS RNA-Binding 
Protein 1) acts as a transcriptional activator and plays a role in the initiation of transcription 
(Bertolotti et al., 1998). The overlap of the rs20417 SNP with these motif sites may have an 
impact on the regulation of gene expression.
The PTGS1 rs5788 SNP showed a protective effect under a dominant model. PTGS1 SNPs 
have been previously studied, but no association with asthma phenotypes (allergic and 
aspirin-intolerant asthma) was found (Shi et al., 2005). This is the first study to report an 
association between the PTGS1 rs5788 SNP and an asthma phenotype. No regulatory 
information was found for that specific SNP.
The major strengths of this study include a well-defined phenotype and examination of 
candidate genes based on their functional role in disease pathogenesis. We were also able to 
test our genetic associations while adjusting for potential independent confounding factors 
such as age, smoking history and exposure duration. The major limitations include small 
sample size due to rarity of DA, lack of information regarding the relative exposure levels of 
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the AW and DA groups and the issue of multiple interferences. Another limitation is that the 
AW controls were younger and had less exposure to diisocyanates than cases. This was 
unintentional due to difficulty in the recruitment of age-matched workplace controls. 
However, the AW group had mean exposure duration of 5.5 years. It has been reported that 
nearly 40% and 60% of subjects exposed to isocyanates become symptomatic within, 
respectively, 1 year and after 5 years of exposure (Malo et al., 1992). Therefore, it is 
reasonable to expect this exposure period to be sufficient for developing DA in susceptible 
individuals. The results were not corrected for multiple comparisons since our analyses were 
based on a priori hypotheses. Instead, we reported all tests that reached the 0.05 level of 
significance.
In conclusion, this case-control study reports, for the first time, an association between DA 
and SNPs in TNFα, FB1, PTGS2 and PTGS1 genes. Further studies are warranted to 
confirm these findings in an independent replication cohort and to characterize the 
functional role of these markers in DA susceptibility.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Demographics of study groups.
Variable DA+ AW
DA+ versus AWs
(p value)
n 95 142
Sex (M/F) 84/11 132/10   0.2499
Age (years, SEM) 42.4, 1.24 30.4, 0.63 <0.0001
Exposure (HDI/MDI/TDI) 53/22/20 142/0/0 <0.0001
Exposure Duration (months, SEM) 144.6, 14.4 65.8, 2.3 <0.0001
Atopy (Yes/No) 56/36 76/54   0.7819
Smoking (Current/Ex/Never) 16/36/43 52/27/63 <0.0001
DA+, exposed workers with SIC confirmed diisocyanate asthma; AW, asymptomatic diisocyanate exposed controls.
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Table 2
Distribution of genotype frequencies between the groups.
Gene/SNP ID*
DA+ (n = 95)
n (%)
AWs (n = 142)
n (%) Fisher’s exact p values
ADAM33 S1 (rs3918396)
 1.1 75 (80.6) 122 (85.9) 0.3661
 1.2 13 (14.0)   17 (12.0)
 2.2   5 (5.4)     3 (2.1)
ADAM33 ST + 5 (rs597980)
 1.1 23 (24.5)   41 (28.9) 0.5444
 1.2 50 (53.2)   65 (45.8)
 2.2 21 (22.3)   36 (25.3)
ADAM33 T1 (rs2280091)
 1.1 70 (74.5) 113 (80.1) 0.1681
 1.2 22 (23.4)   28 (19.9)
 2.2   2 (2.1)     0 (0.00)
ALOX5 (G-1699A) (rs4986832)
 1.1 59 (64.1)   95 (66.9) 0.7180
 1.2 28 (30.4)   42 (29.6)
 2.2   5 (5.4)     5 (3.5)
PTGS1 (C644A) (rs5788)
 1.1 69 (73.4) 102 (72.3) 0.7237
 1.2 20 (21.3)   34 (24.1)
 2.2   5 (5.3)     5 (3.6)
PTGS2 (G-765C) (rs20417)
 1.1 65 (69.1)   91 (64.5) 0.0566
 1.2 23 (24.5)   48 (34.0)
 2.2   6 (6.4)     2 (1.4)
PTGS2 (G3050C) (rs5277)
 1.1 68 (72.3) 105 (74.5) 0.3547
 1.2 26 (27.2)   33 (23.4)
 2.2   0 (0.00)     3 (2.1)
NAG1/GDF15 (H6D) (rs1058587)
 1.1 49 (52.1)   76 (53.9) 0.8561
 1.2 41 (43.6)   57 (40.4)
 2.2   4 (4.3)     8 (5.7)
NAG1/GDF15 (V9L) (rs1059519)
 1.1 41 (43.6)   56 (39.4) 0.6283
 1.2 41 (43.6)   71 (50.0)
 2.2 12 (12.8)   15 (10.6)
IL10 (G-1082A) (rs1800896)
 1.1 27 (29.0)   39 (27.5) 0.3051
 1.2 45 (48.4)   81 (57.0)
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Gene/SNP ID*
DA+ (n = 95)
n (%)
AWs (n = 142)
n (%) Fisher’s exact p values
 2.2 21 (22.6)   22 (15.5)
IL10 (C-819T) (rs1800871)
 1.1 56 (60.2)   72 (51.1) 0.4177
 1.2 31 (33.3)   57 (40.4)
 2.2   6 (6.5)   12 (8.5)
IL1α (G + 4845T) (rs17561)
 1.1 45 (48.4)   78 (54.9) 0.5935
 1.2 38 (40.9)   51 (35.9)
 2.2 10 (10.7)   13 (9.2)
IL1β (C + 3953T) (rs1143634)
 1.1 48 (51.6)   88 (62.0) 0.0635
 1.2 43 (46.2)   46 (32.4)
 2.2   2 (2.2)     8 (5.6)
IL1β (C-511T) (rs16944)
 1.1 38 (40.9)   63 (44.4) 0.8735
 1.2 40 (43.0)   58 (40.8)
 2.2 15 (16.1)   21 (14.8)
IL1 RN (T + 2018C) (rs419598)
 1.1 50 (53.2)   75 (52.8) 1.0000
 1.2 37 (39.4)   56 (39.4)
 2.2   7 (7.4)   11 (7.8)
TGFB (C-509T) (rs1800469)
 1.1 53 (57.0)   63 (44.4) 0.1693
 1.2 30 (32.3)   61 (43.0)
 2.2 10 (10.7)   18 (12.7)
TGFB codon 10 (T/C) (rs1982073)
 1.1 34 (39.1)   55 (39.0) 0.4746
 1.2 33 (37.9)   62 (44.0)
 2.2 20 (23.0)   24 (17.0)
TNF (G-238A) (rs361525)
 1.1 86 (92.5) 129 (90.9) 0.7369
 1.2   7 (7.5)   11 (7.7)
 2.2   0 (0.0)     2 (1.4)
TNFα (G-308A) (rs1800629)
 1.1 56 (60.2) 104 (73.2) 0.0996
 1.2 33 (35.5)   35 (24.7)
 2.2   4 (4.3)     3 (2.1)
*1.1, homozygous for the major allele; 2.2, homozygous for the minor allele; 1.2, heterozygous.
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